TRexBio Inc: Valuation, Funding & Investors
TRexBio is a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue-resident regulatory T cell (Treg) biology. The company leverages computational biology and a proprietary Deep Biology Platform to map human tissue Treg behavior and advance tissue-targeted therapies for autoimmune and inflammatory diseases.
Leadership & Board
- Current Number of Employees
- 62
- Current LinkedIn Followers
- 13,559
Latest Estimated Valuation
- Total Amount Raised
- $50M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $50M
- Latest Funding Round
- Investment
Company Momentum
PositiveTRexBio Inc LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
TRexBio Inc had 62 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
TRexBio Inc had 13,559 followers as of November 16, 2026. The number of followers increased by 41 (0.30%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 27, 2026 | Investment | $50.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| SV Health Investors | Investment |
| Janus Henderson Investors | Investment |
| Eli Lilly and Company | Investment |
| Delos Capital | Investment |
| Alexandria Venture Investments | Investment |
| Avego Bioscience Capital | Investment |
| Polaris Partners | Investment |
| Affinity Asset Advisors | Investment |
Similar Companies
A snapshot of private companies similar to TRexBio Inc, helping you discover and navigate related company profiles.







